News | March 16, 2026
C2N Diagnostics expands Alzheimer’s blood test to South Korea via BeauBrain partnership
Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test
Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test
Over 8.8?million Indians aged 60 and above currently live with dementia,
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
Quest Diagnostics’ blood-based test panels demonstrate confirmatory accuracy, potentially reducing the need for PET imaging
New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency
The study concluded that elevated levels of two proteins help predict how a person will recover from a traumatic brain injury (TBI), providing important information to determine appropriate care
Lung cancer is the leading cause of cancer death in the USA, making up almost 25% of all cancer deaths
It is the first approved blood test that can predict likely progression to Alzheimer's Disease up to six years in advance
Last year, the company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation
It is the first blood test able to detect early-stage Breast Cancer with high accuracy in women above the age of 40 years
Subscribe To Our Newsletter & Stay Updated
